Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.95
+0.44 (7.99%)
At close: Sep 8, 2025, 4:00 PM
6.00
+0.05 (0.84%)
After-hours: Sep 8, 2025, 5:32 PM EDT

Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $247.34 million. The enterprise value is $213.35 million.

Market Cap247.34M
Enterprise Value 213.35M

Important Dates

The last earnings date was Wednesday, August 13, 2025, after market close.

Earnings Date Aug 13, 2025
Ex-Dividend Date n/a

Share Statistics

Immuneering has 41.57 million shares outstanding. The number of shares has increased by 12.61% in one year.

Current Share Class 41.57M
Shares Outstanding 41.57M
Shares Change (YoY) +12.61%
Shares Change (QoQ) +1.28%
Owned by Insiders (%) 21.12%
Owned by Institutions (%) 9.21%
Float 32.79M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 6.85
P/TBV Ratio 10.76
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.14.

Current Ratio 3.70
Quick Ratio 3.52
Debt / Equity 0.14
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -130.47% and return on invested capital (ROIC) is -77.34%.

Return on Equity (ROE) -130.47%
Return on Assets (ROA) -68.37%
Return on Invested Capital (ROIC) -77.34%
Return on Capital Employed (ROCE) -196.73%
Revenue Per Employee n/a
Profits Per Employee -$941,346
Employee Count66
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +403.39% in the last 52 weeks. The beta is 0.43, so Immuneering's price volatility has been lower than the market average.

Beta (5Y) 0.43
52-Week Price Change +403.39%
50-Day Moving Average 4.17
200-Day Moving Average 2.39
Relative Strength Index (RSI) 65.83
Average Volume (20 Days) 994,705

Short Selling Information

The latest short interest is 1.58 million, so 3.80% of the outstanding shares have been sold short.

Short Interest 1.58M
Short Previous Month 1.56M
Short % of Shares Out 3.80%
Short % of Float 4.82%
Short Ratio (days to cover) 3.83

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -64.07M
Pretax Income -56.07M
Net Income -62.13M
EBITDA -63.70M
EBIT -64.07M
Earnings Per Share (EPS) -$1.88
Full Income Statement

Balance Sheet

The company has $26.36 million in cash and $4.00 million in debt, giving a net cash position of $22.35 million or $0.54 per share.

Cash & Cash Equivalents 26.36M
Total Debt 4.00M
Net Cash 22.35M
Net Cash Per Share $0.54
Equity (Book Value) 28.94M
Book Value Per Share 0.80
Working Capital 20.24M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$51.51 million and capital expenditures -$25,685, giving a free cash flow of -$51.53 million.

Operating Cash Flow -51.51M
Capital Expenditures -25,685
Free Cash Flow -51.53M
FCF Per Share -$1.24
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -12.61%
Shareholder Yield -12.61%
Earnings Yield -26.36%
FCF Yield -21.86%

Analyst Forecast

The average price target for Immuneering is $13.00, which is 118.49% higher than the current price. The consensus rating is "Strong Buy".

Price Target $13.00
Price Target Difference 118.49%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) -39.88%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1